C
15.73
-0.06 (-0.38%)
| Previous Close | 15.79 |
| Open | 15.87 |
| Volume | 466,354 |
| Avg. Volume (3M) | 1,099,870 |
| Market Cap | 2,108,968,192 |
| Price / Sales | 197.93 |
| Price / Book | 8.96 |
| 52 Weeks Range | |
| Earnings Date | 12 Nov 2025 |
| Operating Margin (TTM) | -205.18% |
| Diluted EPS (TTM) | -1.88 |
| Total Debt/Equity (MRQ) | 30.55% |
| Current Ratio (MRQ) | 14.37 |
| Operating Cash Flow (TTM) | -162.02 M |
| Levered Free Cash Flow (TTM) | -106.95 M |
| Return on Assets (TTM) | -28.58% |
| Return on Equity (TTM) | -74.44% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Centessa Pharmaceuticals plc | Bearish | Mixed |
AIStockmoo Score
1.0
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 0.5 |
| Average | 1.00 |
|
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 0.50% |
| % Held by Institutions | 94.39% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Index Venture Life Associates Vi Ltd | 30 Jun 2025 | 9,961,789 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 31.00 (Wells Fargo, 97.08%) | Buy |
| Median | 30.00 (90.72%) | |
| Low | 28.00 (Guggenheim, 78.00%) | Buy |
| Average | 29.75 (89.13%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 18.02 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Guggenheim | 06 Oct 2025 | 28.00 (78.00%) | Buy | 23.00 |
| Wells Fargo | 03 Sep 2025 | 31.00 (97.08%) | Buy | 15.91 |
| Chardan Capital | 12 Aug 2025 | 30.00 (90.72%) | Buy | 17.11 |
| 30 Jul 2025 | 30.00 (90.72%) | Buy | 16.56 | |
| Truist Securities | 21 Jul 2025 | 30.00 (90.72%) | Buy | 16.06 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 03 Sep 2025 | Announcement | Centessa Pharmaceuticals to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference |
| 12 Aug 2025 | Announcement | Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025 |
| 12 Aug 2025 | Announcement | Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |